alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
**Exhibit32.2**

CERTIFICATION PURSUANT TO18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THESARBANES-OXLEY ACT OF 2002

The undersigned, theChief Financial Officer of Gladstone Capital Corporation (the “Company”),hereby certifies on the date hereof, pursuant to 18 U.S.C. §1350(a), as adoptedpursuant to Section 906 of The Sarbanes-Oxley Act of 2002, that the QuarterlyReport on Form 10-Q for the quarter ended June 30, 2007 (“Form 10-Q”), filedconcurrently herewith by the Company, fully complies with the requirements ofSection 13(a) or Section 15(d) of the Securities Exchange Act of 1934, asamended, and that the information contained in the Form 10-Q fairly presents,in all material respects, the financial condition and results of operations ofthe Company.

Dated:  August 6, 2007
| /s/ Harry Brill          |   |
|--------------------------|--------|
| Harry Brill              |
| Chief Financial  Officer |

 

----
##### Table of Contents



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
 Washington, DC 20549
 
 FORM 8-K
 CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
 Date of Report (Date of earliest event reported): September 11, 2008
 Valeant Pharmaceuticals International
  Delaware
    
    1-11397
    
    33-0628076(State or Other Jurisdiction of
    
    (Commission File Number)
    
    (IRS Employer Identification No.)Incorporation)
 One Enterprise
Aliso Viejo, California (92656)
(Address of Principal Executive Offices) (Zip Code)
 (949) 461-6000
  o
    
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)o
    
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)o
    
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))o
    
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))




---



TABLE OF CONTENTS  Item 2.01 Completion of Acquisition or Disposition of AssetsItem 9.01 Financial Statements and ExhibitsSIGNATUREINDEX TO EXHIBITSEXHIBIT 99.1    Table of Contents  
 Item 2.01 Completion of Acquisition or Disposition of Assets.
   
 Item 9.01 Financial Statements and Exhibits.
    2.1
    
    Acquisition Agreement, dated August 4, 2008, between Valeant Pharmaceuticals
International, and Meda AB, previously filed as Exhibit 99.1 to the Companys Current
Report on Form 8-K with the Securities and Exchange Commission on August 5, 2008 and
incorporated herein by this reference.2.2
    
    Asset Transfer and License Agreement, dated August 4, 2008, between Valeant
Pharmaceuticals International and Meda AB, previously filed as Exhibit 99.2 to the
Companys Current Report on Form 8-K with the Securities and Exchange Commission on
August 5, 2008 and incorporated herein by this reference.99.1
    
    Press Release of Valeant Pharmaceuticals International, dated September 12,
2008.




---



##### Table of Contents



SIGNATURE
  Valeant Pharmaceuticals InternationalBy:
    /s/ Steve T. MinSteve T. MinExecutive Vice President and
General Counsel




---



##### Table of Contents



INDEX TO EXHIBITS
 Exhibit No.
    
    Description2.1
    
    Acquisition Agreement, dated August 4, 2008, between Valeant Pharmaceuticals
International, and Meda AB, previously filed as Exhibit 99.1 to the Companys
Current Report on Form 8-K with the Securities and Exchange Commission on
August 5, 2008 and incorporated herein by this reference.2.2
    
    Asset Transfer and License Agreement, dated August 4, 2008, between Valeant
Pharmaceuticals International and Meda AB, previously filed as Exhibit 99.2 to
the Companys Current Report on Form 8-K with the Securities and Exchange
Commission on August 5, 2008 and incorporated herein by this reference.99.1
    
    Press Release of Valeant Pharmaceuticals International, dated September 12, 2008
UNITED STATES DEPARTMENT OF TRANSPORTATION 

FEDERAL AVIATION ADMINISTRATION 

WASHINGTON, DC 

MCDONOUGH PROPERTIES, L.L.C. 

M & R HOLDINGS, L.L.C., 

TRI-D, L.L.C., AND COL. FRANK BARNETT 

Complainant, 

v. 

CITY OF WETUMPKA 

Respondent 

FAA Docket No. 16-12-11 

NOTICE OF EXTENSION OF TIME 

This matter is before the Federal Aviation Administration (FAA) based on the abovereferenced complaint, filed in accordance with FAA Rules of Practice for Federally-Assisted 

Airport Enforcement Proceedings, 14 CFR, Part 16. Pursuant to 14 CFR, Part 16, subpart B, 

the date by which the Final Agency Decision will be issued in this matter is hereby extended 

to on or about October 31, 2014. 

An extension of time is necessary and appropriate for a fair and complete determination in this 

case. 

Eduardo Angeles I 

Associate Administrator 

for Airports 
CERTIFICATE OF SERVICE 

I HEREBY CERTIFY that on July 8, 2014, I caused to be placed in the United States 

mail (first class mail, postage paid) a true copy of the Notice of Extension of Time, 

addressed to: 

Counsel for Complainant 

Raymond Veatch, Esq. 

P. 0. Box 302 

Tracys Landing, MD 20779 

Email: manager@intemationalacs.com 

Wade Ramsey, Esq. 

Ramsey & Associates, LLC 

P. 0. Box 382012 

Birmingham, AL 35238 

Email: ~~Js.:n:llill'£,Y~.fL'\!Jli.:\lll2 

Counsel for Respondent 

Pablo 0. Niiesch, Esq. 

Anjali G. Pate, Esq. 

Spiegel & McDiannid, LLP 

1333 New Hampshire Avenue, N.W. 

Washington, DC 20036 

Email: 

Hand Delivered to: 

FAA Part 16 Airport Proceedings Docket 

FAA Airport Compliance and Management Analysis, AC0-1 00 

FAA Southern Region, AS0-600
Exhibit
      32.2





**CERTIFICATION
      OF CHIEF FINANCIAL**


**LEV
      PHARMACEUTICALS, INC.**


**PURSUANT
      TO 18 U.S.C. SECTION 1350, AS ADOPTED**


**PURSUANT
      TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**





In
      connection with the Quarterly Report of Lev Pharmaceuticals, Inc. (the
“Company”) on Form 10-QSB for the period ending September 30, 2006 as filed with
      the Securities and Exchange Commission on the date hereof (the “Report”), I,
      Douglas J. Beck, Chief Financial Officer of the Company, certify, pursuant
      to 18
      U.S.C. ss.1350, as adopted pursuant to ss.906 of the Sarbanes-Oxley Act,
      that:





(1)
          The report fully complies with the requirements of Section
      13(a) or 15(d) of the Securities Exchange Act of 1934; and




(2)
          The information contained in the Report fairly presents, in
      all material respects, the financial condition and result of operations of
      the
      Company.




Date: November
              14, 2006
            By:
            /s/ Douglas
              J. BeckDouglas
              J. BeckChief
                Financial Officer
Court of Appeals of the State of Georgia Clerk's Office, Atlanta, May 04, 2020. I certify that the above is a true extract from the minutes of the Court of Appeals of Georgia. Witness my signature and the seal of said court hereto affixed the day and year last above written. , Clerk. 

# Court of Appeals of the State of Georgia
ATLANTA, May 04, 2020 The Court of Appeals hereby passes the following order A20D0365. CARA WILLIAMS v. THE STATE. Upon consideration of the Application for Discretionary Appeal, it is ordered that it be hereby DENIED.
LC NUMBERS: 18CR1826 18CR848
May 5, 2015 

EPA, Bayer, Syngenta, and Nufarm Meeting on Fenoxaprop Registration Review 

Potomac Yards South Room S-9261 

1100- 1200 

Meeting Agenda: 

I. Introductions 

II. Registration Review Schedule 

III. Risk Mitigation Discussion 

fV. Next Steps 

Meeting Summary: 

• The OPP registration review team for fenoxaprop met with Bayer, Syngenta, and Nufarm, the 

registrants for this post-emergent herbicide, to discuss measures to mitigate risk to non-target 

plants. 

• Discussion focused on the importance of consistent labeling across agricultural labels to address 

herbicide resistance and spray drift management. 

• The EPA team shared documents with the registrants on best management practices (BMPs) for 

boom spraying (by the American Society of Agricultural Engineers) and herbicide resistance (by 

the Weed Science Society of America) prior to this meeting. 

• The Proposed Interim Decision (PID) for fenoxaprop is scheduled to be released for comment in 

June 20 15; the Final Interim Decision is scheduled for December 2015. 

Meeting Participants: 

U.S. EPAPRD: Tracy Perry, Miguel Zavala, Kelly Sherman (BC) 

BEAD: Jihad Alsadek, William Chism, Monisha Kaul 

EFED: Charles Peck, Jean Holmes (BC) 

RD: Grant Rowland, Driss Benmhend 

BayerDanyel Ward, State Registration Manager 

Steven King, Marketing 

Russel Jones, Operations 

Jason Wistehuff, Product Management 

Dana Sargent, Regulatory Affairs 

Charlotte Sanson, Regulatory Affairs 

Brad Glen, Environmental Safety 

Tilghman Hall, Environmental Safety 

Jane Tang, Environmental Safety 

Arlene Cotie, Product Development 

Allan Hovis, Stewardship 

SyngentaTamara Murphy, Regulatory 

Don Porter, Technical Product Lead 

Jerry Wells, Regulatory 

Adora Clark, Stewardship 

Mark Ledson, Product Application 

Nufarm-

' Nathan Eheresman , Regulatory Affairs
Report of Independent Public Accountants

 

To Household Finance Corporation:

We have audited, in accordance with auditing standards generally accepted in the United States, the consolidated financial statements of Household Finance Corporation (the "Company") and subsidiaries as of December 31, 2001 and have issued our report thereon dated January 14, 2002.  We have not audited any financial statements of the Company as of any date or for any period subsequent to December 31, 2001, or performed any audit procedures subsequent to the date of our report on those statements.

In connection with our audit, nothing came to our attention that caused us to believe that the Company was not in compliance with any of the terms, covenants, provisions, or conditions of the Pooling and Servicing Agreement (the "Agreement"), dated May 1, 1996, in conjunction with the Revolving Home Equity Loan Asset Backed Certificates Series 1996-1, insofar as they relate to accounting matters.  It should be noted, however, that our audit was not directed primarily toward obtaining knowledge of such noncompliance.

As a part of our audit, we made a study and evaluation of the Companys system of internal accounting controls over the Companys home equity loan portfolio, including those loans serviced under the Agreement to the extent we considered necessary to evaluate the system as required by generally accepted auditing standards.  In accordance with these standards, the purpose of our study and evaluation, which included obtaining an understanding of the accounting systems, was to determine the nature, timing and extent of the auditing procedures necessary for expressing an opinion on the financial statements.  Our study and evaluation also took into consideration certain of the criteria and audit requirements in the Audit Guide for Audits of Non-Supervised Mortgages Approved by the Department of Housing and Urban Development.  However, certain procedures included in the audit guide are not applicable to the home equity loans being serviced for the Trustee, and therefore, were not performed.

Our audit disclosed no exceptions or errors in records relating to home equity loans serviced for the Trustee that, in our opinion, Section 3.10 of the Agreement required us to report.

This report is intended solely for the information and use of the Board of Directors and management of the Company and should not be used for any other purpose.

Arthur Andersen LLP

Chicago, Illinois

January 14, 2002
**Exhibit****31.1**

 

**CERTIFICATION**

**Pursuantto Section 302 of the Sarbanes-Oxley Act of 2002**

 

I, David Gladstone, certify that:

 

1.  I havereviewed this quarterly report on Form 10-Q of Gladstone Capital Corporation;

 

2.  Based on myknowledge, this quarterly report does not contain any untrue statement of amaterial fact or omit to state a material fact necessary to make the statementsmade, in light of the circumstances under which such statements were made, notmisleading with respect to the period covered by this quarterly report;

 

3.  Based on myknowledge, the financial statements, and other financial information includedin this quarterly report, fairly present in all material respects the financialcondition, results of operations and cash flows of the registrant as of, andfor, the periods presented in this quarterly report;

 

4.  Theregistrant’s other certifying officer(s) and I are responsible for establishingand maintaining disclosure controls and procedures (as defined in Exchange ActRules 13a-15(e) and 15d-15(e)) for the registrant and have:

 

a) designed such disclosure controls and procedures,or caused such disclosure controls and procedures to be designed under oursupervision, to ensure that material information relating to the registrant,including its consolidated subsidiaries, is made known to us by others withinthose entities, particularly during the period in which this quarterly reportis being prepared;

 

b) evaluated the effectiveness of the registrant’sdisclosure controls and procedures and presented in this quarterly report ourconclusions about the effectiveness of the disclosure controls and proceduresas of the end of the period covered by this report based on such evaluation;and

 

c) disclosed in this report any changes in the registrant’sinternal control over financial reporting that occurred during the registrant’smost recent fiscal quarter (the registrant’s fourth fiscal quarter in the caseof an annual report) that has materially affected, or is reasonably likely tomaterially affect the registrant’s internal control over financial reporting;and

 

5.  Theregistrant’s other certifying officer(s) and I have disclosed, based on ourmost recent evaluation of internal control over financial reporting, to theregistrant’s auditors and the audit committee of registrant’s board ofdirectors (or persons performing the equivalent functions):

 

a) All significant deficiencies and materialweaknesses in the design or operation of internal controls over financialreporting which are reasonably likely to adversely affect the registrant’sability to record, process, summarize and report financial data; and

 

b) Any fraud, whether or not material, that involvesmanagement or other employees who have a significant role in the registrant’sinternal control over financial reporting.

 

 

Date: February 9,2005

 
| /s/  DAVID GLADSTONE           |   |
|-------------------------------------|--------|
|  David  Gladstone              |
| Chief Executive  Officer and        |
| Chairman of the  Board of Directors |

 

----
<PAGE>   1
                                                                   EXHIBIT 23.1



                         INDEPENDENT AUDITORS' CONSENT


To the Board of Directors and Shareholders
of Modtech, Inc.:

We consent to the incorporation by reference in the Registration Statement on
Form S-8 of Modtech, Inc. of our report dated March 8, 1996, relating to the
balance sheets of Modtech Inc. as of December 31, 1994 and 1995, and the
related statements of operations, shareholders' equity and cash flows for each
of the years in the three-year period ended December 31, 1995, which report
appears in the December 31, 1995 annual report on Form 10-K of Modtech, Inc.


                                        /s/ KPMG Peat Marwick LLP
                                        -------------------------------

KPMG Peat Marwick LLP
Orange County, California
November 26, 1996
EXHIBIT 32.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002  In connection with the Quarterly Report of instaCare, Corp. (the Company) on Form 10-Q for the quarter ended March 31, 2008, as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Keith Berman, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:  1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and  2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.   /s/ Keith Berman Keith Berman Chief Financial Officer May 14, 2008
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549
 FORM 8-K
 CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
 Date of Report (Date of earliest event reported): January 28, 2009
 NEWPORT CORPORATION
 (Exact name of registrant as specified in its charter)
 Nevada(State or other
jurisdiction of
incorporation)
    
    000-01649(Commission File Number)
    
    94-0849175(IRS Employer Identification No.)
 1791 Deere Avenue, Irvine, California(Address of principal executive offices)
    
    92606(Zip Code)
 (949) 863-3144  (Registrants telephone number, including area code)
 Not Applicable  (Former name or former address, if changed since last report)
  o
    
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 o
    
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 o
    
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 o
    
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))




---



##### 



Item 2.06   Material Impairments.
  (In millions)Goodwill impairment charge
    
    $
    105Impairment charge on certain other intangible assets
    
    
    15Income tax
expense to re-establish valuation allowance and recognize other
deferred tax liabilities
    
    
    25Total anticipated charges
    
    $
    145
 Cautionary Note Regarding Forward-Looking Statements
  SIGNATURES
  NEWPORT CORPORATIONDate:  January 28, 2009
    By:
    /s/ Jeffrey B. CoyneJeffrey B. CoyneSenior Vice President, General Counsel and
Corporate Secretary
amendment3secured.htm




EXHIBIT 4.2


AMENDMENT NO. 3 TO


GREEN BALLAST, INC.


8% SENIOR SECURED NOTE


 

 


THIS AMENDMENT NO. 3, dated as of January 31, 2012 (the “Amendment”), to the 8% Senior Secured Note, dated as of April 15, 2011, as amended from time to time (the “GBL Note”), by Green Ballast, Inc., a Delaware corporation (the “Company”).


 


WHEREAS, the Company issued the GBL Note to Green Ballast LLC, a Tennessee limited liability company (the “Holder”) on April 15, 2011; and


 


WHEREAS, the Company and the Holder desire to enter into this Amendment.


 


NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged and agreed, the Company and the Holder agree as follows:


 


1.  Section 6(a)(vi) of the GBL Note is hereby amended by deleting Section 6(a)(vi) in its entirety and replacing it with the following:


 


vi.           if at any time after March 1, 2012, the Common Stock shall not be eligible for listing or quotation for trading on a Trading Market and shall not be eligible to resume listing or quotation for trading thereon within five (5) Trading Days, or the Company fails to use its best efforts to cause the Common Stock to be listed or quoted on a Trading Market after March 1, 2012; provided however, that in the event the Company (i) files an S-1 to register for resale the Holder’s Common Stock (including the Conversion Shares issuable upon conversion thereof) and (ii) reasonably diligently responds to comments from the Commission or otherwise uses its best efforts to seek effectiveness of the S-1, the Company shall not be deemed to be in default or breach of this Note if the Commission fails to declare the S-1 effective by February 1, 2012, thereby causing to delay or prevent the Common Stock from becoming eligible for listing or quotation for trading on a Trading Market;


 


2. Except to the extent amended hereby, the GBL Note shall remain in full force and effect.


 


3. All capitalized terms used herein, and not otherwise defined herein, have the respective meanings given to such terms in the GBL Note.


 


4. This Amendment may be executed in any number of counterparts, each of which shall constitute an original document.  Electronic signatures, whether by fax, e-mail, or other electronic means, shall be treated as original signatures.


 







 


[Signature page to follow.]


 






  





  











  








IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed the day and year first set forth above.


 


 



 



	 	COMPANY:
	 	 
	 	GREEN BALLAST, INC.





 


 



	 	By:  	/s/ Kevin Adams  






	 	Name:	Kevin Adams
	 	Title: 	Chief Executive Officer





 



 



	 	HOLDER:
	 	 
	 	GREEN BALLAST LLC





 


 



	 	By:  	/s/ Kevin Adams  






	 	Name:	Kevin Adams
	 	Title: 	Chief Executive Officer
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE 10- K
AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
       
<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                              DEC-31-1998
<PERIOD-START>                                 JAN-01-1998
<PERIOD-END>                                   DEC-31-1998
<CASH>                                         10,536
<SECURITIES>                                   0
<RECEIVABLES>                                  115,974
<ALLOWANCES>                                   12,489<F1>
<INVENTORY>                                    277,131
<CURRENT-ASSETS>                               425,989
<PP&E>                                         69,744
<DEPRECIATION>                                 0
<TOTAL-ASSETS>                                 599,377
<CURRENT-LIABILITIES>                          256,247
<BONDS>                                        164,163
<PREFERRED-MANDATORY>                          0
<PREFERRED>                                    0
<COMMON>                                       12
<OTHER-SE>                                     154,286
<TOTAL-LIABILITY-AND-EQUITY>                   599,377
<SALES>                                        359,245
<TOTAL-REVENUES>                               500,816
<CGS>                                          372,728
<TOTAL-COSTS>                                  66,719
<OTHER-EXPENSES>                               (196)
<LOSS-PROVISION>                               0
<INTEREST-EXPENSE>                             21,343
<INCOME-PRETAX>                                40,222
<INCOME-TAX>                                   15,486
<INCOME-CONTINUING>                            24,736
<DISCONTINUED>                                 0
<EXTRAORDINARY>                                599
<CHANGES>                                      0
<NET-INCOME>                                   25,493
<EPS-PRIMARY>                                  2.08
<EPS-DILUTED>                                  2.01
        
<FN>
Net of allowances for doubtful accounts of $12,489. Comprised of long-term debt.
</FN>

</TABLE>
Docket Number FAA-2014-0282